DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Characterization == Nanoparticle drug delivery focuses on maximizing drug efficacy and minimizing cytotoxicity. Fine-tuning nanoparticle properties for effective drug delivery involves addressing the following factors. The surface-area-to-volume ratio of nanoparticles can be altered to allow for more ligand binding to the surface. Increasing ligand binding efficiency can decrease dosage and minimize nanoparticle toxicity. Minimizing dosage or dosage frequency also lowers the mass of nanoparticle per mass of drug, thus achieving greater efficiency. Surface functionalization of nanoparticles is another important design aspect and is often accomplished by bioconjugation or passive adsorption of molecules onto the nanoparticle surface. By functionalizing nanoparticle surfaces with ligands that enhance drug binding, suppress immune response, or provide targeting/controlled release capabilities, both a greater efficacy and lower toxicity are achieved. Efficacy is increased as more drug is delivered to the target site, and toxic side effects are lowered by minimizing the total level of drug in the body. The composition of the nanoparticle can be chosen according to the target environment or desired effect. For example, liposome-based nanoparticles can be biologically degraded after delivery, thus minimizing the risk of accumulation and toxicity after the therapeutic cargo has been released. Metal nanoparticles, such as gold nanoparticles, have optical qualities(also described in nanomaterials) that allow for less invasive imaging techniques.
=== Digital ion trap === The digital ion trap (DIT) is a quadrupole ion trap (linear or 3D) that differs from conventional traps by the driving waveform. A DIT is driven by digital signals, typically rectangular waveforms that are generated by switching rapidly between discrete voltage levels. Major advantages of the DIT are its versatility and virtually unlimited mass range. The digital ion trap has been developed mainly as a mass analyzer.
==== Distribution ==== Tizanidine is extensively distributed throughout the body. Its volume of distribution is 2.4 L/kg following intravenous injection. The drug's plasma protein binding is approximately 30%.
Copernicium is a synthetic chemical element; it has symbol Cn and atomic number 112. Its known isotopes are extremely radioactive, and have only been created in a laboratory. The most stable known isotope, copernicium-285, has a half-life of approximately 30 seconds. Copernicium was first created in February 1996 by the GSI Helmholtz Centre for Heavy Ion Research near Darmstadt, Germany. It was named after the astronomer Nicolaus Copernicus on his 537th anniversary. In the periodic table of the elements, copernicium is a d-block transactinide element and a group 12 element. During reactions with gold, it has been shown to be an extremely volatile element, so much so that it is possibly a gas or a volatile liquid at standard temperature and pressure. Copernicium is calculated to have several properties that differ from its lighter homologues in group 12, zinc, cadmium and mercury; due to relativistic effects, it may give up its 6d electrons instead of its 7s ones, and it may have more similarities to the noble gases such as radon rather than its group 12 homologues. Calculations indicate that copernicium may show the oxidation state +4, while mercury shows it in only one compound of disputed existence and zinc and cadmium do not show it at all. It has also been predicted to be more difficult to oxidize copernicium from its neutral state than the other group 12 elements. Predictions vary on whether solid copernicium would be a metal, semiconductor, or insulator. Copernicium is one of the heaviest elements whose chemical properties have been experimentally investigated.
Sources: en.wikipedia.org
=== Available forms === Pure lorazepam is an almost white powder that is nearly insoluble in water and oil. In medicinal form, it is mainly available as tablets and a solution for injection, but, in some locations, it is also available as a skin patch, an oral solution, and a sublingual tablet. Lorazepam injectable solution is administered either by deep intramuscular injection or by intravenous injection. The injectable solution comes in 1 mL ampoules containing 2 or 4 mg of lorazepam. The solvents used are polyethylene glycol 400 and propylene glycol. As a preservative, the injectable solution contains benzyl alcohol. Toxicity from propylene glycol has been reported in the case of a person receiving a continuous lorazepam infusion. Topical formulations of lorazepam, while sometimes used as a treatment for nausea, especially in people in hospice, has been advised against by the American Academy of Hospice and Palliative Medicine for this purpose as it has not been proven effective.
The Grand Lodge, being only responsible for the first three degrees, does not represent all of Cuban Freemasonry without the Supreme Council, which is responsible for all the higher degrees, from the 4th to the 33rd degrees. Cuban Freemasons considered this as an insult to the Supreme Council, and an attempt to reject the Grand Commander's authority. Cuban Freemasons sent a flood of calls, emails, and letters to the office of Grand Master Zamora Fernández to refuse to meet with the President. On August 23, Zamora Fernández wrote a letter distributed to Cuban Freemasons indicating that the office of the Grand Master had decided not to attend the meeting "...in order to preserve Masonic unity". The Freemason and Cuban activist writer Ángel Santiesteban Prats stated that President Díaz-Canel's full intention was to completely fracture Freemasonry in Cuba. Santiesteban said: "I doth my hat to the Grand Master's wise decision. Masonic unity above all. History is being made... it is a milestone in our country's history, especially over the last 62 years. I remind you that Freemasonry is the only institution in Cuba that didn't dance like puppets on the stage with Fidel Castro and demand the return of that boy Elián. Everybody else gave in. The Abakuás, the spiritists, and the Yoruba Association, they all caved to Castro." On March 28, 2022, Grand Treasurer Francisco Javier Alfonso Vidal was elected as Grand Master of the Grand Lodge of Cuba.
An intern is expected to care for patients with a certain degree of independence but is under the supervision of more senior physicians who may or may not be on location. During each clinical posting the intern is evaluated by senior colleagues and is, if deemed having skills corresponding to the goals set forth by The National Board of Health and Welfare, passed individually on all four postings and may go on to take a written exam on common case presentations in surgery, internal medicine, psychiatry, and general practice. After passing all four main postings of the internship and the written exam, the physician may apply to The National Board of Health and Welfare to be licensed as a Doctor of Medicine. Upon application the physician has to pay a licensing fee of SEK 2,300—approximately equivalent to EUR 220 or USD 270, as per exchange rates on 24 April 2018—out of pocket, as it is not considered to be an expense directly related to medical school and thus is not covered by the state. Physicians who have a foreign medical degree may apply for a license through different paths, depending on whether they are licensed in another EU or EEA country or not.
=== Itching === Itching tends not to be a severe problem when opioids are used for pain relief, but antihistamines are useful for counteracting itching when it occurs. Non-sedating antihistamines such as fexofenadine are often preferred as they avoid increasing opioid induced drowsiness. However, some sedating antihistamines such as orphenadrine can produce a synergistic pain relieving effect permitting smaller doses of opioids be used. Consequently, several opioid/antihistamine combination products have been marketed, such as Meprozine (meperidine/promethazine) and Diconal (dipipanone/cyclizine), and these may also reduce opioid induced nausea.
Urine Tears Perspiration Saliva Respiration Milk Faeces Bile Drugs are excreted from the kidney by glomerular filtration and by active tubular secretion following the same steps and mechanisms as the products of intermediate metabolism. Therefore, drugs that are filtered by the glomerulus are also subject to the process of passive tubular reabsorption. Glomerular filtration will only remove those drugs or metabolites that are not bound to proteins present in blood plasma (free fraction) and many other types of drugs (such as the organic acids) are actively secreted. In the proximal and distal convoluted tubules, non-ionised acids and weak bases are reabsorbed both actively and passively. Weak acids are excreted when the tubular fluid becomes too alkaline and this reduces passive reabsorption. The opposite occurs with weak bases. Poisoning treatments use this effect to increase elimination, by alkalizing the urine causing forced diuresis which promotes excretion of a weak acid, rather than it getting reabsorbed. As the acid is ionised, it cannot pass through the plasma membrane back into the blood stream and instead gets excreted with the urine. Acidifying the urine has the same effect for weakly basic drugs. On other occasions drugs combine with bile juices and enter the intestines. In the intestines the drug will join with the unabsorbed fraction of the administered dose and be eliminated with the faeces or it may undergo a new process of absorption to eventually be eliminated by the kidney.
Sources: en.wikipedia.org
The unlikely geminal diol species CH3C(OH)+2 is stable in these environments. For aqueous solutions the pH scale is the most convenient acidity function. Other acidity functions have been proposed for non-aqueous media, the most notable being the Hammett acidity function, H0, for superacid media and its modified version H− for superbasic media. In aprotic solvents, oligomers, such as the well-known acetic acid dimer, may be formed by hydrogen bonding. An acid may also form hydrogen bonds to its conjugate base. This process, known as homoconjugation, has the effect of enhancing the acidity of acids, lowering their effective pKa values, by stabilizing the conjugate base. Homoconjugation enhances the proton-donating power of toluenesulfonic acid in acetonitrile solution by a factor of nearly 800. In aqueous solutions, homoconjugation does not occur, because water forms stronger hydrogen bonds to the conjugate base than does the acid.
=== Differential diagnosis === Several other disorders and diseases present themselves with symptoms like JIA. These causes include, but are not limited to, infectious (for example, septic arthritis or osteomyelitis) and post-infectious conditions (reactive arthritis, acute rheumatic fever, and in some geographic areas Lyme disease); hematologic and neoplastic diseases such as leukemia or bony tumors; and other connective tissue diseases (such as systemic lupus erythematosus). For the systemic-onset form of JIA, the differential diagnosis also includes Kawasaki disease and periodic fever syndromes. Some genetic skeletal dysplasias, such as forms of mucopolysaccharidosis, especially type 1 Scheie syndrome, progressive pseudo-rheumatoid dysplasia, and multicentric osteolysis, nodulosis, and arthropathy syndrome may also mimic JIA, as they may present with joint swelling, joint restriction, stiffness, and pain. The clinical and radiologic overlap between genetic skeletal dysplasias and JIA can be great that molecular analysis may be needed to confirm the diagnosis. Rarely, metabolic diseases, such as Farber disease, may also mimic JIA. Patients with Farber disease typically have subcutaneous nodules and a hoarse or weak voice due to laryngeal nodules.
Nitrogen forms nine molecular oxides, some of which were the first gases to be identified: N2O (nitrous oxide), NO (nitric oxide), N2O3 (dinitrogen trioxide), NO2 (nitrogen dioxide), N2O4 (dinitrogen tetroxide), N2O5 (dinitrogen pentoxide), N4O (nitrosylazide), and N(NO2)3 (trinitramide). All are thermally unstable towards decomposition to their elements. One other possible oxide that has not yet been synthesised is oxatetrazole (N4O), an aromatic ring. Nitrous oxide (N2O), better known as laughing gas, is made by thermal decomposition of molten ammonium nitrate at 250 °C. This is a redox reaction and thus nitric oxide and nitrogen are also produced as byproducts. It is mostly used as a propellant and aerating agent for sprayed canned whipped cream, and was formerly commonly used as an anaesthetic. Despite appearances, it cannot be considered to be the anhydride of hyponitrous acid (H2N2O2) because that acid is not produced by the dissolution of nitrous oxide in water. It is rather unreactive (not reacting with the halogens, the alkali metals, or ozone at room temperature, although reactivity increases upon heating) and has the unsymmetrical structure N–N–O (N≡N+O−↔−N=N+=O): above 600 °C it dissociates by breaking the weaker N–O bond. Nitric oxide (NO) is the simplest stable molecule with an odd number of electrons. In mammals, including humans, it is an important cellular signalling molecule involved in many physiological and pathological processes. It is formed by catalytic oxidation of ammonia.
Rats that were fed a standard diet showed a progressive degradation of myelin, on day 14 post DAI it was evident that myelin sheaths have collapsed, dissolved or disappeared from the injured axons. For the axons with remaining myelin, the myelin was becoming thinner. Rats that were served ketogenic diets presented axons with thicker myelin in comparison to the standard diet rats. The marker that was used to determine axonal injury in this study was amyloid precursor protein (APP). Rats that were fed a standard diet and an uptake of APP, leading to an increase in damaged/injured axons.
== External links == [1]: A MATLAB routine to solve the linear elastic contact mechanics problem entitled; "An LCP solution of the linear elastic contact mechanics problem" is provided at the file exchange at MATLAB Central. [2]: Contact mechanics calculator. [3]: detailed calculations and formulae of JKR theory for two spheres. [5]: A Matlab code for Hertz contact analysis (includes line, point and elliptical cases). [6]: JKR, MD, and DMT models of adhesion (Matlab routines).
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.